Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abbreviated, absent, acid, aclinical, adult, affinity, agonist, aldesleukin, algorithm, allogenic, alpha, Altor, amino, amortizable, andconditionally, andmore, andother, antagonist, antitumor, Apollo, arbitration, assemble, assembled, AstraZeneca, attacked, autoimmune, autoimmunity, Avenue, axicabtagene, bacteria, belief, beta, biased, bindingof, biochemical, BioNTech, BioScience, BLA, blinatumomab, borrowing, BPCIA, bya, byinhibiting, carcinogenicity, carcinoma, Celgene, centered, checkpoint, ciloleucel, communicable, contact, contamination, contrast, corona, credible, crystal, cultivated, cytokine, danger, de, deep, default, Delinquent, diligent, diligently, disagree, dispute, dissuade, durable, dynamic, East, Eastlake, effector, effortsto, eliminatedfor, encompassing, endothelial, entail, enteringinto, epidemic, escalation, evade, evolution, exacerbate, external, extrapolate, fastest, field, fierce, fold, folding, forgo, fourth, fromtheir, globe, goodwill, governmentaland, ground, Guide, guided, harmfulmalware, havean, hormone, hypotension, idealized, immunoregulatory, immunotherapy, impactthat, implicit, impressive, includingunpatented, inconclusive, incremental, ineffective, inflamed, informationor, inhibitory, inmoving, inour, insight, inter, interact, interaction, interchangeable, interface, interleukin, intermolecular, inventory, invite, ipilimumab, IRC, jointly, judgement, justify, killer, labor, larger, leader, leadproduct, leak, legacy, licensure, lieu, ligand, liver, lot, malignant, marketplace, Medicenna, melanoma, mental, metastatic, microbial, microenvironment, mimetic, mimic, modest, modifynative, molecular, molecularly, monotherapy, mount, multinational, murine, native, necessitate, Nektar, neoleukin, Neoleukinde, Neoleukinplatform, neurotoxicity, nextdecade, nil, NK, NLTX, NME, noncompetitive, nonexclusive, notable, novo, novocytokine, novoprotein, nullification, obsolete, occupy, ofseveral, ona, opposed, orcommercialize, orphan, orUW, Ourlead, ourproprietary, outbreak, output, overhead, pandemic, partiallymitigate, pause, PBCIA, pediatric, penetration, pharmacodynamic, PHSA, plc, potent, PREA, precisely, precursor, precursorsto, preferential, preferentially, problematic, productcandidate, protectionand, proteolytic, protracted, proven, provisional, raw, RCC, receptor, recombinant, recombinanthuman, refined, refractory, regimen, relapsed, relatedto, relevantjurisdiction, remeasured, renal, renamed, renew, reproductive, resembling, resistance, resource, respectto, ripple, robust, Roche, RSU, safer, Sanofi, satisfactorily, Seattle, sequence, slower, smaller, spreadof, Squibb, stable, Stanford, steric, stimulationof, storm, strain, strict, stricter, subset, substituted, substitution, substitutionfor, subunitof, surgery, syngeneic, Synthorx, talent, task, testingof, therefrom, thereto, thermodynamic, ticker, tisagenlecleucel, toadminister, toadvance, tobuild, toincur, topline, torecombinant, traditional, transplantation, trialsfor, trialsusing, tyrosine, understood, uniform, unmarketable, Unregistered, unresolved, unsafe, unstable, unviable, usecertain, UW, validateand, validateor, variantsof, vascular, vast, VEGF, vendor, verification, vi, viral, Washington, widen, widespread, window, withinthe, Wuhan, Xencor
Removed:
abroad, accompanied, accomplish, adapt, added, adhere, administer, administering, affiliated, age, alleging, alter, amenable, appealing, AQXP, arrange, ASU, atopic, attain, Australia, baseline, BCCA, bladder, Box, burdensome, captioned, career, check, chronic, clearance, collected, Competent, complicated, complied, complying, comprising, compromise, compromised, considerably, continual, COPD, copyright, core, corrective, corroborated, damaging, Dear, declare, decree, dedicated, defer, deliver, dependency, detailing, detain, deviating, Directorate, disaggregation, disapproval, discontinuance, dissolution, diverse, domain, double, driven, dropping, earn, educating, EEA, establishment, estate, ethically, eventually, execution, failing, female, fewer, fixed, Flagship, fluctuate, gathered, golden, Great, guaranteed, hedging, hierarchy, highest, holding, impermissible, imposing, ineligibility, injunction, input, insert, inside, institution, instrument, insufficiency, interrupt, interstate, interstitial, invalidity, inventorship, investigating, invoice, IPO, irreversible, irrevocably, Kinship, Korea, landscape, lawsuit, library, lipopolysaccharide, liquidated, liquidation, losing, lowest, LP, LPS, marked, mg, mid, mild, moderate, morbidity, mortality, motivate, move, multicenter, narrowing, negotiating, nonbinding, nonclinical, nonrenewal, Northern, observable, obstructive, orderly, Outsourcing, pain, parachute, participating, patented, patenting, persuasive, pertinent, placebo, pool, practically, preempted, prefer, prematurely, prevalence, profit, profitably, progressed, prone, proposing, proving, pulmonary, quoted, randomized, ranged, recordkeeping, redesigned, relator, reliable, reorganization, repealed, Replacing, representative, restitution, returning, role, score, screening, scrutinized, secondary, seize, settle, shipping, shortage, Silicon, solidify, specialty, statistical, statistically, STI, strive, sublicensed, sublicensing, supplier, SVB, synthesize, thereunder, TPD, train, transparent, typical, unacceptably, unadjusted, unclear, uncured, underwent, unenforceability, uninterpretable, unobservable, unpredictability, unrealized, unreliable, USA, usage, useable, Valley, varied, verifiable, warrant, Welfare
Filing tables
Filing exhibits
Related press release
Associated NGNE transcripts
NGNE similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration StatementsNos.333-194490,333-203179,333-210172,333-216572,333-223589 and333-234734 on FormS-8 and Nos.333-215457 and333-223584 on FormS-3 of our report dated March 12, 2020, relating to the financial statements of Neoleukin Therapeutics, Inc. appearing in this Annual Report on Form10-K of Neoleukin Therapeutics, Inc. for the year ended December 31, 2019.
/s/ Deloitte LLP
Chartered Professional Accountants
Vancouver, Canada
March 12, 2020
123